Drugs / ICP-538
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07535099 | Mar → Sep 2026 overdue | — | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-09 | Beijing InnoCare Pharma Tech Co., Ltd. | Regulatory 诺诚健华宣布ICP-538成为中国首款获批临床的VAV1分子胶降解剂 innocarepharma.com ↗
今天宣布，公司自主研发的VAV1分子胶降解剂ICP-538获国家药品监督管理局（NMPA）药品审评中心（CDE）批准开展临床研究。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-02-09 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华宣布ICP-538成为中国首款获批临床的VAV1分子胶降解剂 innocarepharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICP-538 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07535099 ↗ |